Champions Oncology Reports Record Quarterly Revenue of $10.1 Million

Dec 15, 2020 4:57:58 PM / by Champions Oncology

HACKENSACK, NJ / ACCESSWIRE / December 14, 2020 / Champions Oncology, Inc.

(NASDAQ:CSBR), a leading global oncology technology solutions provider engaged in transforming drug discovery through innovative pharmacology, biomarker and data platforms, today announced its financial results for the second fiscal quarter ended October 31, 2020.

Second Quarter and Recent Highlights:

  • Launched our Lumin Bioinformatics proprietary SaaS platform
  • Delivered record quarterly revenue of $10.1 million, an increase of 33% year-over-year
  • Reported income from operations, excluding stock-based compensation, depreciation and amortization, of $400,000
  • Raising our full-year revenue guidance to 20%-25%
Read More →

Champions Oncology Announces the Launch of Lumin Bioinformatics, Its New Oncology Data-Driven SaaS Program

Nov 17, 2020 12:36:06 PM / by Champions Oncology

HACKENSACK, NJ / ACCESSWIRE / November 16, 2020 / Champions Oncology, Inc. (NASDAQ:CSBR), a leading global oncology technology solutions provider that is transforming drug discovery through innovative pharmacology, biomarker and data platforms, announced today the launch of its new proprietary SaaS program known as Lumin Bioinformatics. By leveraging Champions' large cancer dataset, which is unique for its substantial depth of characterization, combined with many other published cancer datasets, Lumin provides users with a vast database of tumor characterization that can be used for computational research. The software, which is purchased as a yearly subscription, also provides sophisticated analytic tools that are utilized to interrogate the data for associations between molecular and various phenotypic features, including thousands of drug responses, clinical annotations, prior treatment histories, and genetic dependencies. Insights developed using Lumin can provide the basis for biomarker hypotheses, reveal potential mechanisms of therapeutic resistance, and guide the direction of additional preclinical evaluations.

Read More →

Champions Oncology Expands Its Immuno-Oncology Research Offering by Launching a Unique Autologous Tumor Infiltrating Lymphocyte Ex Vivo Platform

Nov 11, 2020 3:57:55 PM / by Champions Oncology

HACKENSACK, NJ / ACCESSWIRE / November 11, 2020 / Champions Oncology, Inc. (NASDAQ:CSBR), a leading global oncology technology solutions provider that is transforming drug discovery through innovative pharmacology, biomarker and data platforms, announced today the launch of a novel autologous immuno-oncology (IO) research platform. This autologous tumor infiltrating lymphocyte (TIL) ex vivo platform centers on the use of a tumor and an immune system derived from the same patient for investigations in the immuno-oncology space.

Read More →

Champions Oncology Reports Record Quarterly Revenue of $9.5 Million

Sep 16, 2020 10:12:27 AM / by Champions Oncology

Hackensack, NJ – September 14, 2020 – Champions Oncology, Inc. (Nasdaq: CSBR), engaged in an end-to-end range of research and development technology solutions and services to improve the development and use of oncology drugs, today announced its financial results for the first fiscal quarter ended July 31, 2020.

Read More →

Champions Oncology Reports Quarterly Revenue of $8.8 Million

Jul 29, 2020 2:57:35 PM / by ManagingTeam

Record Annual Revenue of $32.1 Million

HACKENSACK, NJ / ACCESSWIRE / July 27, 2020 / Champions Oncology, Inc. (NASDAQ:CSBR), engaged in an end-to-end range of research and development technology solutions and services to improve the development and use of oncology drugs, today announced its financial results for the year and fourth fiscal quarter ended April 30, 2020.

Read More →

Champions Oncology Reports Record Quarterly Revenue of $9.0 Million

Mar 19, 2020 4:45:15 PM / by ManagingTeam

HACKENSACK, NJ / ACCESSWIRE / March 12, 2020 / Champions Oncology, Inc. (CSBR), engaged in an end-to-end range of research and development technology solutions and services to improve the development and use of oncology drugs, today announced its financial results for the third fiscal quarter ended January 31, 2020.

Read More →

The Children’s Cancer Therapy Development Institute is Collaborating with Champions Oncology and Jackson Laboratory to provide RACEact/PREA Pediatric Cancer Study Plan Services

Jan 29, 2020 10:00:00 AM / by Champions Oncology

The Children’s Cancer Therapy Development Institute (cc-TDI), Champions Oncology, and The Jackson Laboratory offer rapid, cost-effective services to the pharma, biopharma and biotech industry– speeding the right drug to the right pediatric cancer whenever possible.

Read More →

Champions Oncology and PhenoVista Biosciences Announce a Strategic Partnership to provide Oncology Imaging-Based Phenotypic Assays for Preclinical Drug Development

Nov 13, 2019 10:00:00 AM / by Champions Oncology

Hackensack, NJ – November 13, 2019 – Champions Oncology (NASDAQ: CSBR), an end-to-end R&D Oncology solutions company announced today that they have entered into a strategic partnership with PhenoVista Biosciences.

Read More →

Champions Oncology Partners with TransCure bioServices to Expand European Business and Operations

May 30, 2019 10:00:00 AM / by Champions Oncology

HACKENSACK, NJ – May 30, 2019  –  Champions Oncology, Inc. (NASDAQ: CSBR), engaged in an end-to-end range of research and development technology solutions and services to improve the development and use of oncology drugs, today announced they have partnered with TransCure bioServices to expand the pharmacology operations of Champions’ translational oncology tools throughout Europe.

Read More →

Champions Oncology Reports Record Quarterly Revenue of $6.2 Million

Sep 13, 2018 10:00:00 AM / by Champions Oncology

Reiterates Expectations for Revenue Growth of at Least 20% for Fiscal Year 2019

 Hackensack, NJ – September 13, 2018 – Champions Oncology, Inc. (Nasdaq: CSBR), engaged in an end-to-end range of research and development technology solutions and services to improve the development and use of oncology drugs, today announced its financial results for the first fiscal quarter ended July 31, 2018.

Read More →